

Accelerated disassembly of IgE–receptor complexes by a disruptive macromolecular inhibitor

Beomkyu Kim^{1*}, Alexander Eggel^{2*}, Svetlana S. Tarchevskaya¹, Monique Vogel², Heino Prinz³ & Theodore S. Jardetzky¹

IgE antibodies bind the high-affinity IgE Fc receptor (FcεRI), found primarily on mast cells and basophils, and trigger inflammatory cascades of the allergic response^{1,2}. Inhibitors of IgE–FcεRI binding have been identified and an anti-IgE therapeutic antibody (omalizumab) is used to treat severe allergic asthma^{3,4}. However, preformed IgE–FcεRI complexes that prime cells before allergen exposure dissociate extremely slowly⁵ and cannot be disrupted by strictly competitive inhibitors. IgE–Fc conformational flexibility indicated that inhibition could be mediated by allosteric or other non-classical mechanisms^{6–8}. Here we demonstrate that an engineered protein inhibitor, DARPin E2_79 (refs 9–11), acts through a non-classical inhibition mechanism, not only blocking IgE–FcεRI interactions, but actively stimulating the dissociation of preformed ligand–receptor complexes. The structure of the E2_79–IgE–Fc₃₋₄ complex predicts the presence of two non-equivalent E2_79 sites in the asymmetric IgE–FcεRI complex, with site 1 distant from the receptor and site 2 exhibiting partial steric overlap. Although the structure is indicative of an allosteric inhibition mechanism, mutational studies and quantitative kinetic modelling indicate that E2_79 acts through a facilitated dissociation mechanism at site 2 alone. These results demonstrate that high-affinity IgE–FcεRI complexes can be actively dissociated to block the allergic response and suggest that protein–protein complexes may be more generally amenable to active disruption by macromolecular inhibitors.

The IgE antibody Fc, comprising three domains (Cε2–Cε3–Cε4), binds the α-chain of FcεRI (FcεRIα) with subnanomolar affinity (<1 nM)^{1,2}. The IgE–Fc Cε3 domains contact receptor directly and can adopt multiple conformational states, ranging from closed to open forms^{6–8,12}, which could have an impact on FcεRI binding and potential receptor complex dynamics. In an effort to characterize different IgE ligands and mechanisms of FcεRI inhibition, we developed a fluorescence binding assay that distinguishes IgE ligands using a site-specific reporter fluorophore. A double mutant (C328A/K367C) of the IgE–Fc Cε3–Cε4 protein (IgE–Fc₃₋₄) was labelled with Alexa Fluor 488 at residue 367 (referred to as AF488–Fc), which is adjacent to the FcεRIα binding site (Supplementary Fig. 1). AF488–Fc exhibited systematic fluorescence quenching with increasing concentrations of FcεRIα (Fig. 1a), yielding a dissociation constant (K_d) of ~22 nM (Supplementary Table 1), consistent with the lower affinity of the C328A mutation¹³. FcεRIα-directed inhibitors, such as unlabelled IgE–Fc₃₋₄ and anti-FcεRIα antibody (monoclonal antibody 15.1)^{14,15}, reversed receptor-induced fluorescence quenching (Fig. 1b, c and Supplementary Table 1),

IgE-directed inhibitors, including the anti-IgE antibody omalizumab (Xolair)^{3,4}, a 34-nucleotide DNA aptamer (D17.4)^{16,17}, and DARPin E2_79 (refs 9–11), yielded three inhibition profiles. Omalizumab induced fluorescence quenching comparable to FcεRIα (Fig. 1d and Supplementary Table 1), consistent with its binding an epitope overlapping the FcεRIα site^{18,19}. E2_79 restored the receptor-quenched

fluorescence signal (Fig. 1e and Supplementary Table 1), similar to FcεRIα binding inhibitors (Fig. 1b, c). D17.4 did not quench or compete with FcεRIα, but in an indirect competitive binding experiment with AF488–Fc, FcεRIα and unlabelled wild-type IgE–Fc₃₋₄, D17.4 induced systematic fluorescence quenching (Fig. 1f and Supplementary Table 1),




Figure 1 | A fluorescence-quenching assay reveals different classes of IgE-directed inhibitors. **a**, AF488–Fc fluorescence is quenched by FcεRIα. RFU, relative fluorescence units. **b**, Unlabelled IgE–Fc₃₋₄ competes for FcεRIα binding (filled circles, solid line) but has no effect on AF488–Fc alone (open circles, dotted line). **c**, The anti-FcεRIα antibody mAb15.1 competes for FcεRIα binding (filled circles, solid line) but has no effect on AF488–Fc fluorescence (open circles, dotted line). **d**, Omalizumab quenches AF488–Fc fluorescence similar to FcεRIα. **e**, E2_79 competes for FcεRIα binding (filled circles, solid line) but does not affect AF488–Fc fluorescence (open circles, dotted line). **f**, D17.4 competes in assays containing AF488–Fc, FcεRIα and wild-type IgE–Fc₃₋₄, by binding IgE–Fc₃₋₄ competitor (filled circles, solid line). Error bars represent standard deviations of replicate measurements.

¹Department of Structural Biology, Stanford University School of Medicine, Stanford, California 94305, USA. ²Institute of Immunology, University of Bern, CH-3010 Bern, Switzerland. ³Max-Planck-Institut für Molekulare Physiologie, Otto-Hahn-Str. 11, 44227 Dortmund, Germany.

*These authors contributed equally to this work.

consistent with D17.4 binding to wild-type IgE-Fc₃₋₄ but not AF488-Fc. These data indicated that D17.4 and omalizumab act as direct competitive inhibitors, but E2_79 was a candidate allosteric inhibitor.

We determined the 4.3 Å crystal structure of E2_79 bound to IgE-Fc₃₋₄ (Supplementary Table 2) using a cysteine mutant (C335) that locks the Fc into a closed conformational state²⁰. E2_79 binds the IgE Cε3 domain and does not directly engage residues involved in FcεRIα binding (Fig. 2a, b). E2_79 interactions extend throughout the Cε3 domain, including the Cε3-Cε4 domain linker and encroaching on FcεRIα-binding loops (Fig. 2a, c).

To examine the structural basis for E2_79 inhibition, we superimposed the E2_79 structure onto the IgE-Fc-FcεRIα complex using the IgE Cε3 domains. The IgE-Fc-FcεRIα complex is asymmetric, defining two distinct E2_79 sites (Fig. 2b). In the complex, site 1 is entirely exposed, with E2_79 and FcεRIα separated by ~20 Å and no steric overlap (Fig. 2b), indicating the potential for simultaneous E2_79 and FcεRIα binding. For site 2, three E2_79 and five FcεRIα residues make contacts <3.5 Å (Supplementary Table 3), causing partial steric overlap.

We generated three E2_79 double mutants (E20A/R23A, Y45A/W46A and E126A/D127A) to probe the inhibition mechanism (Fig. 2c). E20 and R23 are located adjacent to the Cε3-Cε4 domain linker and could affect the Cε3 domain conformational state, allosterically inhibiting FcεRIα. Y45 and W46 are in the hydrophobic interface with the IgE Fc, and are probably important for binding affinity. E126 and D127 account for most of the predicted steric conflicts with FcεRI

at site 2 (Supplementary Table 3) and could potentially interact with the FcεRI FG binding loop containing R427, contributing to the inhibition. The E20A/R23A and E126A/D127A mutants exhibited similar binding affinity to IgE Fc compared to wild-type E2_79 (Fig. 3a, b), whereas the Y45A/W46A mutant showed significantly reduced binding affinity (Fig. 3c). The inhibition activities of the E20A/R23A and E126A/D127A mutants remained similar compared to that of wild-type E2_79 (Fig. 3d, e), indicative of a non-allosteric model. The Y45A/W46A mutant exhibited no inhibition (Fig. 3f), as expected from its lack of binding (Fig. 3c). The mutants validated the crystal structure, and indicated that E2_79 inhibition is not due to Cε3-Cε4 linker or FcεRI binding loop interactions.

To investigate binding of E2_79 to the IgE-FcεRIα complex, we conducted Biacore experiments that revealed a marked acceleration of complex disassembly. FcεRIα was coupled to the chip, then loaded with either full-length IgE (Sus11) or IgE-Fc₃₋₄ proteins (Supplementary Fig. 2). The monoclonal anti-IgE antibody Le27 recognizes a non-inhibitory epitope in the IgE Cε4 domain, and binding to the preformed IgE-FcεRIα complexes was readily observed (Supplementary Fig. 2a, e). In contrast, E2_79, but not controls, stimulated rapid dissociation of both Sus11 and IgE-Fc₃₋₄ complexes (Supplementary Fig. 2b-d, f-h).




Figure 2 | DARPin E2_79 binds IgE-Cε3 domains outside the FcεRIα binding site. **a**, Crystal structure of the E2_79 (light blue) and C335 IgE-Fc₃₋₄ (pale yellow) complex. **b**, Structure of the IgE-Fc₃₋₄-FcεRIα complex oriented similarly to **a**. FcεRIα (purple) binds asymmetrically, and two non-equivalent E2_79 binding sites (1 and 2) are indicated. **c**, Residues in E2_79 at the interface with the IgE-Fc₃₋₄ are shown as beige sticks. Mutated residues (E20, R23, Y45, W46, E126 and D127) are shown as red sticks. The FcεRIα binding loops (BC, DE and FG) in the Cε3 domain are indicated.




Figure 3 | Binding and inhibition activities of E2_79 mutants. **a**, The E20A/R23A mutant exhibits a binding affinity similar to wild-type E2_79. **b**, The E126A/D127A mutant binds similarly to wild-type E2_79. **c**, The Y45A/W46A mutant exhibits a loss of binding to IgE-Fc₃₋₄. **d**, The E20A/R23A mutant inhibits FcεRIα binding similar to wild-type E2_79. **e**, The E126A/D127A mutant inhibits FcεRIα binding similar to wild-type E2_79. **f**, The Y45A/W46A mutant does not inhibit FcεRIα binding. Direct binding (**a-c**) was measured by ELISA. Inhibition was measured using the fluorescence quenching assay (**d-f**). Error bars represent standard deviations of replicate measurements.

E2_79 and FcεRIα binding to IgE are linked by a six state coupled binding reaction scheme (Fig. 4a, b), in which two E2_79 molecules and one FcεRIα protein can potentially assemble into a quaternary complex with IgE. We considered three potential mechanisms to explain the accelerated complex dissociation: (1) a classic competitive inhibition mechanism operating solely through steric conflicts at site 2; (2) an allosteric mechanism operating through both site 1 and site 2; (3) a facilitated dissociation mechanism in which E2_79 binding to IgE–FcεRIα complexes only at site 2 stimulates complex dissociation. Model 3 represents a competitor-induced dissociation mechanism²¹ in which a subset of ligand attachment points that become exposed during partial complex dissociation can be engaged by an exogenously added competitor, thereby accelerating the intrinsic dissociation rate. This has been named ‘facilitated dissociation’²². To discriminate quantitatively between the three inhibition mechanisms, we developed the complete reaction schemes as COPASI biochemical network models²³, allowing the simulation of the time-dependent evolution of the reaction

pathways and intermediates, as well as global curve fitting and parameter estimation with the surface plasmon resonance (SPR) data.

The classic competitive inhibition mechanism is not consistent with the SPR data, but predicts high-affinity binding of E2_79 to site 1 and no acceleration of IgE release from the chip surface (Supplementary Fig. 3a, b). Simulations for this model are similar to the experimental observations with the Le27 antibody (Supplementary Fig. 2a, e). In this model, E2_79 competition is only mediated by site 2, where steric hindrance prevents E2_79 binding to IgE–FcεRIα complexes. Relaxation to a new equilibrium occurs with the unaccelerated, slow dissociation rate of the complex.

For the allosteric model, we posited that both site 1 and site 2 would contribute to FcεRIα inhibition and the acceleration of complex dissociation. In this model, E2_79 binding to sites 1 and 2 in the IgE–FcεRIα complex should both exhibit reduced affinity associated with the allosteric coupling. Similarly, both site 1 and site 2 binding by E2_79 would induce reduced affinity and increased dissociation rates




Figure 4 | Kinetic modelling of SPR data points to a facilitated dissociation mechanism for E2_79. **a**, Reaction scheme for the allosteric model. Blue arrows indicate that IgE–FcεRIα complex dissociation is accelerated by E2_79 binding to site 1 and site 2. **b**, Reaction scheme for the facilitated dissociation model. The blue arrow indicates that IgE–FcεRIα complex dissociation is only accelerated by E2_79 binding to site 2. **c**, **d**, Best global curve fitting result for the allosteric model, shown with seven concentrations of E2_79 (**c**), or the 100 nM

and 200 nM E2_79 concentration curves (**d**). **e**, **f**, Best global curve fitting result for the facilitated dissociation model, shown with seven concentrations of E2_79 (**e**), or the 100 nM and 200 nM E2_79 concentration curves (**f**). Rate and equilibrium dissociation constants highlighted in yellow were fit as described in Methods. In panels **c**–**f**, black circles represent SPR data, fitted curves are coloured blue, and green triangles represent residual differences.

for FcεRIα (Fig. 4a). Owing to this allosteric coupling, IgE–FcεRIα complexes should not have any high-affinity binding sites for E2₇₉.

For the facilitated dissociation model, we posited that E2₇₉ binding to site 1 is not affected by FcεRIα binding, consistent with the predicted >20 Å distance between these proteins (Figs 2b and 4b). There is also correspondingly no change in FcεRIα binding affinity associated with E2₇₉ binding to site 1. The rate constants for both of these binding steps were initially set to the experimentally determined rate constants for E2₇₉ and FcεRIα binding in the absence of the other ligand. In this model, only the binding affinity of E2₇₉ at site 2 is reduced by FcεRIα, through this non-classical competition mechanism. Similarly, there must be a corresponding reduction in FcεRIα binding affinity in the quaternary E2₇₉–IgE–FcεRIα–E2₇₉ complex. Importantly, in this model, site 1 retains native high affinity for E2₇₉ in the IgE–FcεRIα complex, whereas only site 2 exhibits reduced E2₇₉ affinity and the ability to accelerate FcεRIα dissociation. This distinguishes it from the allosteric model, which lacks any high-affinity E2₇₉ sites in the complex.

The initial 120 s of SPR data for IgE–Fc₃₋₄ (Supplementary Fig. 2h), covering E2₇₉ concentrations from 100 nM to 10 μM, were simultaneously fit using the allosteric and facilitated dissociation COPASI models. Curve fitting (Fig. 4c–f) demonstrates that only the facilitated dissociation mechanism captures the biphasic behaviour of the SPR traces accurately. The SPR data exhibit a ~50 resonance units (RU), E2₇₉-concentration-dependent association phase within the first 10–20 s that cannot be modelled by the full allosteric mechanism (Fig. 4c, d). Whereas both models fit the later concentration-dependent dissociation rates for the IgE–FcεRIα complexes, the initial 10–20 s demonstrate an association that corresponds to the presence of the high-affinity binding of E2₇₉ to the exposed site 1 within the IgE–FcεRIα complex. Given the robustness of the fitting, we allowed site 1 kinetic constants in the facilitated dissociation model to vary from experimental values for both E2₇₉ and FcεRIα (Supplementary Table 4). This provided slightly improved curve fitting, and the fitted E2₇₉ site 1 kinetic constants remained close to those determined for the independently binding ligand, further validating this model over an allosteric one.

Non-classical or allosteric inhibitors have the general potential to not only block receptor–ligand binding, but to also engage and actively dissociate preformed receptor complexes. For the IgE–FcεRIα interaction, the activated release of receptor-bound antibody on the surface of effector cells might prove beneficial in treating acute allergic reactions. Here we demonstrated that the E2₇₉ DARPIn is a disruptive inhibitor that binds to IgE–FcεRIα complexes, markedly accelerating their dissociation orders of magnitude over the unaccelerated intrinsic rate.

It has been proposed that facilitated dissociation occurs through competition for subsite attachment points within a ligand-binding site, which become partially exposed before full ligand dissociation^{21,22}. In principle, competitor-induced acceleration of ligand dissociation can be explained by multiple mechanisms, such as allosteric or facilitated dissociation mechanisms considered here, but few observations have been fully examined by both structural and kinetic methods. Small-molecule inhibitors of TNF have been shown to accelerate the dissociation of TNF trimers^{24,25}, potentially intercalating into the trimeric interface. It has been suggested, and it is probably commonly assumed, that larger macromolecular inhibitors depend on complete dissociation of protein complexes and would be unlikely to engage partially dissociated intermediates, potentially providing a ‘kinetic advantage’ to small-molecule protein interaction inhibitors²⁵. However, the E2₇₉-induced dissociation of IgE–FcεRIα complexes indicates that macromolecular therapeutics may have untapped potential as disruptive inhibitors. Antibody-induced complex dissociation has been observed, but specific mechanisms and requirements for such accelerated dissociation have not been fully investigated^{26–28}. Facilitated dissociation may also have an unappreciated role in naturally evolved macromolecular complex disassembly processes.

METHODS SUMMARY

IgE and FcεRIα were produced in insect cells, whereas E2₇₉ was produced in *Escherichia coli* as described¹⁰. Other proteins or DNA ligands (omalizumab, Mab15-1, D17.4, Sus11) were purchased or obtained as described in Methods. IgE–Fc₃₋₄ and E2₇₉ mutants were generated by site-directed mutagenesis and confirmed by DNA sequencing. Fluorescence binding experiments and ELISA assays were performed using a Synergy 4 multi-mode plate reader (BioTek), with labelled AF488–Fc produced as described in Methods. Diffraction data for the IgE–Fc₃₋₄–C335–E2₇₉ complex was collected at the Advanced Light Source beamline 8.3.1 and the structure solved by molecular replacement. SPR assays were conducted with a BIAcore X100 machine and evaluated with BIAevaluation and COPASI²³ software.

Full Methods and any associated references are available in the online version of the paper.

Received 14 December 2011; accepted 3 September 2012.

Published online 28 October 2012.

- Kraft, S. & Kinet, J. P. New developments in FcεRI regulation, function and inhibition. *Nature Rev. Immunol.* **7**, 365–378 (2007).
- Gould, H. J. & Sutton, B. J. IgE in allergy and asthma today. *Nature Rev. Immunol.* **8**, 205–217 (2008).
- D’Amato, G., Buccichioni, E., Oldani, V. & Canonica, W. Treating moderate-to-severe allergic asthma with a recombinant humanized anti-IgE monoclonal antibody (Omalizumab). *Treat. Respir. Med.* **5**, 393–398 (2006).
- Chang, T. W. The pharmacological basis of anti-IgE therapy. *Nature Biotechnol.* **18**, 157–162 (2000).
- Holdom, M. D. *et al.* Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcεRI. *Nature Struct. Mol. Biol.* **18**, 571–576 (2011).
- Dhaliwal, B. *et al.* Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FcεRI. *Proc. Natl Acad. Sci. USA* **109**, 12686–12691 (2012).
- Wurzburg, B. A. & Jardetzky, T. S. Conformational flexibility in immunoglobulin E–Fc₃₋₄ revealed in multiple crystal forms. *J. Mol. Biol.* **393**, 176–190 (2009).
- Wurzburg, B. A., Garman, S. C. & Jardetzky, T. S. Structure of the human IgE–Fc Cε3–Cε4 reveals conformational flexibility in the antibody effector domains. *Immunity* **13**, 375–385 (2000).
- Eggel, A., Baumann, M. J., Amstutz, P., Stadler, B. M. & Vogel, M. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. *J. Mol. Biol.* **393**, 598–607 (2009).
- Baumann, M. J., Eggel, A., Amstutz, P., Stadler, B. M. & Vogel, M. DARPins against a functional IgE epitope. *Immunol. Lett.* **133**, 78–84 (2010).
- Eggel, A. *et al.* Inhibition of ongoing allergic reactions using a novel anti-IgE DARPIn–Fc fusion protein. *Allergy* **66**, 961–968 (2011).
- Garman, S. C., Wurzburg, B. A., Tarchevskaya, S. S., Kinet, J. P. & Jardetzky, T. S. Structure of the Fc fragment of human IgE bound to its high-affinity receptor FcεRIα. *Nature* **406**, 259–266 (2000).
- Basu, M. *et al.* Purification and characterization of human recombinant IgE–Fc fragments that bind to the human high affinity IgE receptor. *J. Biol. Chem.* **268**, 13118–13127 (1993).
- Wang, B. *et al.* Epidermal Langerhans cells from normal human skin bind monomeric IgE via FcεRI. *J. Exp. Med.* **175**, 1353–1365 (1992).
- Mirkin, I., Schweighoffer, T. & Kricek, F. Inhibition of human cord blood-derived mast cell responses by anti-FcεRI Mab 15/1 versus anti-IgE Omalizumab. *Immunol. Lett.* **109**, 120–128 (2007).
- Mendonsa, S. D. & Bowser, M. T. *In vitro* selection of high-affinity DNA ligands for human IgE using capillary electrophoresis. *Anal. Chem.* **76**, 5387–5392 (2004).
- Wiegand, T. W. *et al.* High-affinity oligonucleotide ligands to human IgE inhibit binding to Fcε receptor I. *J. Immunol.* **157**, 221–230 (1996).
- Zheng, L. *et al.* Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab. *Biochem. Biophys. Res. Commun.* **375**, 619–622 (2008).
- Wright, J. D. & Lim, C. Prediction of an anti-IgE binding site on IgE. *Protein Eng.* **11**, 421–427 (1998).
- Wurzburg, B. A. *et al.* An engineered disulfide bond reversibly traps the IgE–Fc₃₋₄ in a closed, non-receptor binding conformation. *J. Biol. Chem.* <http://dx.doi.org/10.1074/jbc.M112.407502> (2012).
- Prinz, H. & Striessnig, J. Ligand-induced accelerated dissociation of (+)-cis-diltiazem from L-type Ca²⁺ channels is simply explained by competition for individual attachment points. *J. Biol. Chem.* **268**, 18580–18585 (1993).
- Gutfreund, H. *Kinetics for the Life Sciences. Receptors, Transmitters and Catalysts* (Cambridge Univ. Press, 1995).
- Hoops, S. *et al.* COPASI—a COMplex Pathway Simulator. *Bioinformatics* **22**, 3067–3074 (2006).
- He, M. M. *et al.* Small-molecule inhibition of TNF-α. *Science* **310**, 1022–1025 (2005).
- Wells, J. A. & McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces. *Nature* **450**, 1001–1009 (2007).
- Wang, C. C. *et al.* Negative and positive site-site interactions, and their modulation by pH, insulin analogs, and monoclonal antibodies, are preserved in the purified insulin receptor. *Proc. Natl Acad. Sci. USA* **85**, 8400–8404 (1988).

27. Lowenthal, J. W. *et al.* High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. *J. Immunol.* **135**, 3988–3994 (1985).
28. Boulain, J. C. & Menez, A. Neurotoxin-specific immunoglobulins accelerate dissociation of the neurotoxin-acetylcholine receptor complex. *Science* **217**, 732–733 (1982).

Supplementary Information is available in the online version of the paper.

Acknowledgements We thank B. Wurzburg and other past and present members of the Jardetzky Laboratory. This research was supported in part by an NIH research grant (AI-18939) and an American Asthma Foundation Senior Investigator Award as well as the Swiss National Science Foundation grant number 310030_127350 to T.S.J. We also thank C. A. Dahinden and B. M. Stadler and members of their groups for valuable discussions. Furthermore, we thank M. J. Baumann for technical support and Molecular

Partners AG, especially P. Amstutz, M. T. Stumpp, P. Forrer and D. Steiner, for placing DARPin libraries at our disposal and providing scientific support.

Author Contributions B.K., A.E., S.S.T. and T.S.J. designed and performed experiments. B.K., A.E., S.S.T., H.P. and T.S.J. analysed data. B.K., S.S.T., A.E., M.V. and T.S.J. contributed reagents. B.K., S.S.T., A.E., M.V., H.P. and T.S.J. discussed/commented on results and edited the manuscript. B.K., A.E. and T.S.J. wrote the manuscript and Supplementary Information, and prepared the figures.

Author Information The structure factors and model for the E2_79–C335 IgE complex have been deposited in the Protein Data Bank under accession code 4GRG. Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to T.S.J. (tjardetz@stanford.edu).

METHODS

Mutagenesis. IgE-Fc₃₋₄ mutants for the fluorescence assay (C328A/G335C, C328A/K367C, T369C and R427C) were generated by site-directed mutagenesis (QuickChange kit, Stratagene) or made commercially (Mutagenix) and confirmed by DNA sequencing. We refer to the resulting double C328A/G335C and C328A/K367C IgE-Fc₃₋₄ mutant proteins as C335 IgE-Fc₃₋₄ and C367 IgE-Fc₃₋₄, respectively. E2_79 mutations (E20A/R23A, Y45A/W46A, W89A and E126A/D127A) were introduced into the original E2_79 gene⁹⁻¹¹. The E2_79 mutants for the binding assays were generated by site-directed mutagenesis (QuickChange kit, Stratagene) and confirmed by DNA sequencing.

Expression and purification of proteins. Expression and purification of the soluble FcεRI α-chain ectodomain was carried out as previously described^{12,29}. Omalizumab (Xolair) was purchased from Novartis. MAb15.1 (anti-FcεRIα) was a gift from the Kinet laboratory. Selection and characterization of the DARPin E2_79 has been reported elsewhere¹⁰. Expression and purification of the E2_79 mutants were carried out as previously described¹⁰. The IgE-Fc₃₋₄ cysteine mutants were expressed in insect cells. The wild-type IgE-Fc₃₋₄, C367 and C335 IgE-Fc₃₋₄ proteins were cloned into pENTRIA (Invitrogen) using a KpnI-XhoI fragment and transferred into the BaculoDirect C-term Linear DNA by using LR Clonase II Enzyme Mix (Invitrogen). Recombinant baculoviruses expressing wild-type and C367 IgE-Fc₃₋₄ proteins were generated using BaculoDirect C-term Transfection Kit (Invitrogen). Recombinant virus was selected and amplified following standard protocols. The wild-type and C367 IgE-Fc₃₋₄ proteins include 3 non-native residues (ADP) generated by the construct at the N terminus and 48 non-native residues including a V5 epitope and a histidine affinity tag (His tag) at the C terminus. For protein production, Hi5 insect cells were grown to a density of 1.3–1.5 million cells ml⁻¹ and infected with the recombinant baculovirus stocks coding for wild-type and mutant IgE-Fc₃₋₄ proteins. Cell supernatants were collected 2.5–3 days after infection and filtered through a Durapore 0.45 µm filter (Millipore). The supernatants were incubated with Ni-NTA agarose (Invitrogen) at room temperature for 3 h, and then loaded into a column. The column was rinsed with 4–5 column volumes of the washing buffer (50 mM Tris (pH 8), 50 mM imidazole, and 300 mM NaCl), and IgE-Fc₃₋₄ was eluted directly with the elution buffer (50 mM Tris (pH 8), 200 mM imidazole, and 300 mM NaCl). The samples were dialysed and concentrated in buffer (50 mM Tris (pH 8) and 50 mM NaCl) using an Amicon ultrafiltration device (Millipore) to a protein concentration of 1 mg ml⁻¹. Proteins were quantified using a Nanodrop spectrophotometer using an extinction coefficient of $\epsilon = 1.32 \text{ cm}^{-1} (\text{mg ml}^{-1})^{-1}$ at 280 nm⁸. To remove the C-terminal tag residues, purified IgE-Fc₃₋₄ was concentrated to 2–3 mg ml⁻¹ and treated with 5–10 U recombinant enterokinase (Invitrogen) per 1 mg protein at room temperature overnight. The enzyme was removed using Ekapture agarose (Novagen).

Dye labelling of AF488-Fc. Purified C367 IgE-Fc₃₋₄ was incubated with three molar equivalents of TCEP (Tris(2-Carboxyethyl)phosphine) at room temperature for 1 h. After TCEP treatment, the presence of free thiol groups in the C367 was confirmed using a thiol and sulphide quantification kit (Molecular Probes). Cysteine-reactive Alexa Fluor 488 (maleimide derivative) was purchased from Invitrogen/Molecular Probes and dissolved in DMSO (dimethyl sulphoxide) at a concentration of 1 mg ml⁻¹. The C367 IgE-Fc₃₋₄ was incubated with 5 molar equivalents of Alexa Fluor 488, at 4 °C overnight. Unreacted dye was removed by gel filtration on a Superdex 200 column (GE Healthcare) equilibrated in buffer (50 mM Tris (pH 8) and 50 mM NaCl).

Fluorescence measurements. Fluorescence experiments were performed using a Synergy 4 multi-mode plate reader (BioTek) in black 96-well Costar fluorescence plates (Corning) in assay buffer (50 mM Tris (pH 8), 50 mM NaCl, 0.1% (v/v) Tween-20, and 100 nM BSA (bovine serum albumin)) at room temperature. Fluorescence was measured using an excitation wavelength of 488 nm and emission was monitored at 520 nm. All samples were incubated at room temperature for at least 10 min before measurement. All measurements were recorded in duplicate. Data obtained were analysed and plotted using KaleidaGraph (Synergy). Binding constants (K_d) of FcεRIα and omalizumab, and half-maximal effective concentrations (EC_{50}) of wild-type IgE-Fc₃₋₄, mAb15.1, D17.4 and E2_79 were obtained by fitting the experimental data to a standard Michaelis–Menten model. The oligonucleotide ligand (D17.4)¹⁷ was synthesized by the PAN Facility (Stanford University School of Medicine).

To monitor fluorescence quenching, each well in a black plate contained 1 µg ml⁻¹ AF488-Fc and increasing concentrations of FcεRIα (0–200 nM) or omalizumab (0–250 nM) in the fluorescence buffer in a total volume of 100 µl. For direct competition assays, each well in a black 96-well plate contained 1 µg ml⁻¹ AF488-Fc, 50 nM FcεRIα, and one of the following competitors: unlabelled wild-type IgE-Fc₃₋₄ (0–200 nM), mAb15.1 (0–100 nM) and E2_79 (0–200 nM). FcεRIα and competitors (except for mAb15.1) were mixed together, and AF488-Fc was added

last. For competition assays with mAb 15.1, AF488-Fc and mAb15.1 were mixed together, and FcεRIα was added last.

For the double competition assay with D17.4, each well in a black 96-well plate contained 1 µg ml⁻¹ AF488-Fc, 50 nM unlabelled wild-type IgE-Fc₃₋₄, 50 nM FcεRIα, and increasing concentrations of D17.4 (0–200 nM) in the fluorescence buffer in a final volume of 100 µl. D17.4 ligand was annealed at 70 °C and cooled before use. The AF488-Fc and unlabelled wild-type IgE-Fc₃₋₄ were mixed together, and then 50 nM FcεRIα and D17.4 were added last together.

Biacore binding assays. SPR assays were conducted with a BIAcore X100 machine and evaluated with BIAevaluation Software, as well as the specific COPASI models described below. Recombinant FcεRIα, corresponding to a previously described N- and C-terminal fusion of FcεRIα with human serum albumin¹⁰, was coupled to the CM5 chip surface. The surface of both flow cells on the CM5 chip were activated with EDC + NHS (both flow cells). Target was injected only in flow cell 2 at 10 µg ml⁻¹ until the target response of 2,500 RU or 700 RU was reached. The surfaces of both flow cells were deactivated with ethanolamine. In all experiments the response (nonspecific binding) in flow cell 1 is subtracted from the signal of flow cell 2. 10 nM IgE was injected for 2 min. The maximal response ($t = 360 \text{ s}$) is set to 0. The off-rate of IgE (buffer flow) was observed for 3 min. As the interaction of IgE with FcεRIα is very high affinity ($\sim 1 \times 10^{-10} \text{ M}$), almost no off-rate is observable in this short time. Thus, the baseline is very stable (almost horizontal), providing an ideal condition to test the binding of a third molecule to the FcεRIα–IgE complex. Different concentrations of anti-IgE molecules were tested. For each measurement new IgE was added to the immobilized FcεRIα as the chip surface was regenerated (stripped) after each run (each concentration of every binder) with 50 mM NaOH. The anti-IgE molecules were injected for 2 min. Dissociation was again observed for 3 min. E2_79 as well as control IgG were tested with FcεRIα alone (without IgE) and no binding was observed.

Protein crystallization. The C335 IgE-Fc₃₋₄–E2_79 complex was concentrated to $\sim 10 \text{ mg ml}^{-1}$ in buffer (50 mM Tris (pH 8) and 50 mM NaCl) using Vivaspins 500 (Sartorius) concentrators, and the final concentration was confirmed using a Nanodrop spectrophotometer (Nanodrop Technologies) with a theoretical absorbance of 0.1% of 1.108 at 280 nm. Initial crystallization conditions were found by sitting-drop vapour diffusion at room temperature using Qiagen JCSG Core Suite screens (Qiagen), and optimized by hanging-drop vapour diffusion methods. The best crystals of C335 IgE-Fc₃₋₄–E2_79 were obtained in 1–3 days by mixing 0.5 µl of protein mixed with 0.5 µl of reservoir solution (0.1 M phosphate-citrate (pH 4.2), 5% (w/v) PEG-3000, 25% (v/v) 1,2-propanediol, 10% (v/v) glycerol; final pH of ~ 5) and incubating over 600 µl of reservoir solution. The crystals were transferred into harvest buffer (0.1 M phosphate-citrate (pH 4.2), 8% (w/v) PEG-3000, 25% (v/v) 1,2-propanediol, 10% (v/v) glycerol), and then flash-cooled in liquid nitrogen.

X-ray data collection, molecular replacement and refinement. Data were collected on beamline 8.3.1 at the Advanced Light Source. All data were indexed, integrated, and scaled using the programs Denzo and Scalepack in the HKL2000 suite³⁰. The C335–E2_79 crystal grew in space group $P3_2$, with unit cell dimensions $a = 71.3 \text{ Å}$, $b = 71.3 \text{ Å}$, $c = 178.5 \text{ Å}$ and $\gamma = 120^\circ$. The structure was solved by molecular replacement with Phaser³¹, using high-resolution crystal structures of the C335 IgE-Fc₃₋₄ (ref. 20) and a homologous DARPin (Protein Data Bank accession 3HG0) as the starting models. Iterative rounds of coordinate and B-factor refinement were done with Refmac, interspersed with manual model building in Coot³². The final model was refined to $\sim 4.3 \text{ Å}$ with statistics collected in Supplementary Table 2. The geometry of the complex model was assessed using MolProbity³³ and PROCHECK³⁴.

ELISA binding assays with E2_79 mutants. 100 µl of purified IgE-Fc₃₋₄ was incubated in microtitre plates overnight at 4 °C at a concentration of 1 µg ml⁻¹ in 0.05 M sodium carbonate buffer. Plates were rinsed and blocked by the same procedures used in the FcεRI binding assay. E2_79 mutants (E20A/R23A, Y45A/W46A and E126A/D127A) containing a His-tag were added at concentrations ranging from 0 nM to 200 nM or 400 nM in duplicate to wells coated with the purified IgE-Fc₃₋₄. The binding of E2_79 containing the His-tag to plate-bound IgE-Fc₃₋₄ was monitored using anti-His tag antibody (Novagen, 70796-3) as a primary antibody and anti-mouse IgG HRP conjugated antibody (R&D system, HAF007) as the secondary antibody. The anti-His tag antibody in a 1:1,000 dilution was incubated after washing for 1 h at room temperature, and then, the anti-mouse IgG HRP conjugated antibody was incubated after washing for 1 h at room temperature. Plates were washed and developed using TMB single solution (Invitrogen, 00-2023). Microplates were read using a Synergy 4 multi-mode plate reader (BioTek) at 650 nm.

COPASI modelling. The COPASI software package for quantitative modelling of biochemical networks³⁵ was used to build the full reaction schemes presented in Fig. 4 and Supplementary Fig. 3. The model consists of eight species and seven reactions within a single compartment. Global quantities were defined, corresponding to on/off

rates for the reaction steps associated with each mechanism, a consolidated 'Biacore output' (RU_{calc}) corresponding to reaction intermediates bound to the chip surface, a fractional mass weighting constant (F_{ME}) to account for E2_79 chip-bound species and overall scaling (k_{ov}) and baseline constants (C_0) for fitting the experimental SPR data. The Biacore output (RU_{calc}) represents a combination of the three receptor-bound species affecting the SPR measurements and was defined mathematically as:

$$RU_{calc} = k_{ov} * ([IgE-Fc\epsilon RI]_t + (1 + F_{ME}) * [E2_79-IgE-Fc\epsilon RI]_t + (1 + 2 * F_{ME}) * [E2_79-IgE-Fc\epsilon RI-E2_79]_t) + C_0$$

where $[IgE-Fc\epsilon RI]_t$, $[E2_79-IgE-Fc\epsilon RI]_t$ and $[E2_79-IgE-Fc\epsilon RI-E2_79]_t$ represent the time-dependent evolution of these reaction species as numerically simulated by COPASI, using the specific model restrictions. Biacore data were extracted using the BiaEvaluation software and imported directly into COPASI for parameter estimation. Each kinetic time course includes 120 data points (seconds), corresponding to a total of 840 data points for the simultaneous fitting of the model parameters. Data fitting was carried out with all available convergence methods, with best results obtained with simulated annealing, particle swarm, Hook & Jeeves, and Levenberg-Marquardt algorithms. The stable convergence of these multiple methods to similar end points was taken as an indicator of the robustness of the fitting and the convergence to a common, global minimum. Experimentally determined rate constants for E2_79 and Fc ϵ RI α were determined in independent Biacore experiments and allowed to vary by 2–3-fold during the data fitting. E2_79 concentrations used experimentally were also allowed to vary

up to 25% and F_{ME} was allowed to vary from 0 to 1. For the allosteric model, kinetic rate constants for site 1 and site 2 E2_79-IgE-Fc ϵ RI α complexes were set to be equivalent. These four parameters were allowed to vary freely, along with k_{ov} and C_0 yielding a total of six freely varying parameters. For the initial fitting of the facilitated dissociation model, kinetic rate constants for site 1 were restricted to experimentally determined values for E2_79 binding in the absence of Fc ϵ RI α , and only the four kinetic constants associated with site 2 E2_79-IgE-Fc ϵ RI α -E2_79 complexes were allowed to vary freely, also yielding a total of six freely varying parameters. For the full fitting of the facilitated dissociation model, kinetic rate constants for both site 1 and site 2 complexes were allowed to vary widely, yielding a total of 10 highly varying parameters.

29. Garman, S. C., Kinet, J. P. & Jardetzky, T. S. Crystal structure of the human high-affinity IgE receptor. *Cell* **95**, 951–961 (1998).
30. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. in *Methods Enzymol.* Vol. 276 (eds Carter, J. C. W. & Sweet, R. M.) 307–326 (Academic, 1997).
31. McCoy, A. J. *et al.* Phaser crystallographic software. *J. Appl. Crystallogr.* **40**, 658–674 (2007).
32. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. *Acta Crystallogr. D* **60**, 2126–2132 (2004).
33. Chen, V. B. *et al.* MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr. D* **66**, 12–21 (2010).
34. Laskowski, R. A., Rullmann, J. A., MacArthur, M. W., Kaptein, R. & Thornton, J. M. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. *J. Biomol. NMR* **8**, 477–486 (1996).